Sarepta Pops on More Positive Data

Shares of development-stage biotech Sarepta Therapeutics  (NASDAQ: SRPT  )  popped 4.3% today after the company released data from the extension phase of its phase 2b clinical study for its Duchenne muscular dystrophy drug eteplirsen. Like most stocks in this space, Sarepta faces a number of risks; eteplirsen, for instance, is the company's main asset, and any setbacks to its development, regulatory delays, or safety issues could make shares plunge. Also, Sarepta is running a very small clinical trial and it may not be able to file for accelerated approvalHowever, to date, the drug has displayed a clean safety profile and continues to show efficacy. In the following video, health-care analyst Max Macaluso discusses these topics and what today's news means for investors.

It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long-term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2499299, ~/Articles/ArticleHandler.aspx, 11/27/2014 11:36:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement